Open AccessHaploidentical hematopoietic stem cell transplantation may improve long-term survival for children with high-risk T-cell acute lymphoblastic leukemia in first complete remission
Author(s) -
Yongzhan Zhang,
Lu Bai,
Yifei Cheng,
AiDong Lu,
Yu Wang,
Jun Wu,
Xiaohui Zhang,
Yingxi Zuo,
Lei Xu,
Yueping Jia,
XiaoJun Huang,
Leping Zhang
Publication year - 2022
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001999
Subject(s) - medicine , cumulative incidence , hematopoietic stem cell transplantation , cohort , chemotherapy , transplantation , retrospective cohort study , oncology , incidence (geometry) , physics , optics
The role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in children with high-risk (HR) T-cell acute lymphoblastic leukemia (T-ALL) in first complete remission (CR1) is still under evaluation. Moreover, relapse is the main factor affecting survival. This study aimed to explore the effect of allo-HSCT (especially haploidentical HSCT [haplo-HSCT]) on improving survival and reducing relapse for HR childhood T-ALL in CR1 and the prognostic factors of childhood T-ALL in order to identify who could benefit from HSCT.